

Available online at www.sciencedirect.com

SciVerse ScienceDirect

journal homepage: www.elsevier.com/locate/crvasa

Review Article

Coronary artery ectasia



Ozgur Ulas Ozcan*, Sadi Gulec

Department of Cardiology, Ankara University, Ankara, Turkey

ARTICLE INFO

Article history:

Received 26 November 2012

Received in revised form

12 January 2013

Accepted 15 January 2013

Available online 20 January 2013

Keywords:

Aneurysm

Atherosclerosis

Coronary artery

Ectasia

ABSTRACT

Coronary artery ectasia (CAE) is defined as localized or diffuse dilatation of coronary artery lumen exceeding the largest diameter of an adjacent normal vessel more than 1.5 fold. The incidence of CAE is reported as 0.3–4.9% of patients undergoing coronary angiography. The rate of recognition may increase with the use of new non-invasive imaging methods like computed tomography (CT) and magnetic resonance (MR) coronary angiography. Atherosclerosis is considered as the main etiologic factor responsible for more than 50% of cases in adults while Kawasaki disease is the most common cause in children or young adults. Coronary ectasia is thought to be a result of exaggerated expansive remodeling, which is eventuated as a result of enzymatic degradation of the extracellular matrix and thinning of the vessel media. Patients with CAE without significant coronary narrowing may present with angina pectoris, positive stress tests or acute coronary syndromes. Ectatic vessel may be an origin of thrombus formation with distal embolization, vasospasm or vessel rupture. The prognosis of CAE depends directly on the severity of the concomitant coronary artery disease. Antiplatelet drugs underlie the therapy. Other management strategies in CAE involve both the prevention of thromboembolic complications and percutaneous or surgical revascularization.

© 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.

Contents

1. Introduction	243
2. Epidemiology and classification	243
3. Etiology and pathophysiology	243
4. Diagnosis	244
5. Clinical significance and symptoms	244
6. Prognosis	245
7. Treatment	245
8. Conclusion	246
References	246

*Correspondence to: Oveciler, 1042nd Street, 45/14, 06460 Cankaya, Ankara, Turkey. Tel.: +90 312 508 2523; Mob.: +90 505 707 7670.
E-mail address: ozgurulasozcan@yahoo.com.tr (O.U. Ozcan).

1. Introduction

Coronary artery ectasia (CAE) is a well-recognized but relatively uncommon finding encountered during diagnostic coronary angiography [1–3]. It is commonly defined as inappropriate dilation of the coronary arteries exceeding the largest diameter of an adjacent normal vessel more than 1.5 fold [1,4] (Fig. 1). The term ‘ectasia’ refers to diffuse dilation of a coronary artery whilst focal dilation is called as ‘coronary aneurysm’ [5]. Even though several mechanisms are suggested the pathophysiology of CAE is still underrecognized. Similarly no consensus exists about the natural history and management of this condition because of the relative scarcity of data. CAE represents not only an anatomical variant but also a clinical constellation of coronary artery disease (CAD) like association with myocardial ischemia and acute coronary syndromes. The purpose of this review is to update and summarize the clinical features of CAE.

2. Epidemiology and classification

Incidence of CAE detected by means of coronary arteriogram has been found to vary between 0.3% and 4.9% [1,3]. In the largest series from the CASS registry, Swaye et al. found CAE in 4.9% of coronary angiograms and the incidence is higher in men than in women (2.2% vs. 0.5% respectively) [3] and postmortem incidence is given 1.4%. Advent of new non-invasive technologies such as computed tomography (CT) and magnetic resonance (MR) coronary angiography, may increase the rate of recognition [6]. Zeina et al. found the prevalence of CAE 8% by coronary CT angiography [7]. Markis suggested a classification of CAE according to the number and diffuseness of involved coronary vessels (Table 1) [7,8]. According to the diameter of the vessel lumen CAE is classified as small (<5 mm), medium (5–8 mm) or giant (>8 mm).




Fig. 1 – Ectasia of right coronary artery (arrow) in a 78 yo female patient.

Table 1 – Markis classification of coronary artery ectasia.

Types of CAE	Definition
Type 1	Diffuse ectasia of two or three vessels
Type 2	Diffuse ectasia in one vessel and localized disease in another
Type 3	Diffuse ectasia in one vessel only
Type 4	Localized or segmental involvement

Table 2 – Etiology of coronary artery ectasia.

- Atherosclerosis
- Coronary artery revascularisation procedures (balloon angioplasty, stent implantation, laser angioplasty, atherectomy, brachytherapy)
- Vasculitides (Kawasaki disease, polyarteritis nodosa, syphilis, Takayasu disease, Wegener granulomatosis, Giant cell arteritis, Churg Strauss Syndrome)
- Congenital malformations
- Chest traumas
- Connective tissue disorders (rheumatoid arthritis, Systemic lupus erythematosus, scleroderma, ankylosing spondylitis, Behçet's disease, Psoriasis)
- Collagenopathies (Marfan's syndrome, Ehlers-Danlos syndrome, hereditary hemorrhagic telangiectasia)
- Primary hyperaldosteronism

3. Etiology and pathophysiology

Atherosclerosis is considered as the main etiologic factor responsible for more than 50% of cases in adults [1,3,4,7,9] while Kawasaki disease is the most common cause in children or young adults [6–8]. Etiology of CAE is demonstrated in Table 2 [10,11]. There are marked histopathological similarities between ectasia and atherosclerosis. Arterial lumen may be narrowed, preserved or dilated with progression of atherosclerosis. The exact mechanism of luminal dilation in some atherosclerotic vessels is unclear while atherosclerosis predominantly causes narrowing of the vessel lumen. Certain plaques, as a result of a phenomenon so called ‘arterial remodeling’, do not reduce luminal size, presumably because of expansion of the media and external elastic membrane [12]. This finding also may be operative in the case of ectasia or aneurysm of other vessels. Observations with the use of intravascular ultrasound demonstrated that arterial remodeling may be bidirectional according to the expansion or shrinkage of external elastic membrane (i.e. positive and negative remodeling respectively) [12]. Positive (or expansive) remodeling is principally a compensatory mechanism to preserve luminal size during the progression of atherosclerosis. CAE is thought to be a result of exaggerated expansive remodeling in which both external elastic membrane and luminal size increase [11,13]. Enzymatic degradation of the extracellular matrix by matrix-metalloproteinases and other lytic enzymes and thinning of the tunica media associated with severe chronic inflammation is suggested as the key pathogenetic mechanism of the exaggerated expansive remodeling. The severity of the changes in the media correlates positively with the diameter

of ectasia. No evidence of ectasia is observed in cases with intact and uninvolved media layer [11]. CAE is associated with overexpression of matrix metalloproteinases [14]. Significantly higher levels of C-reactive protein (CRP) [15] and vascular endothelial growth factor (VEGF) [16] were found among patients with CAE, which suggests more severe and extensive inflammation and neovascularization in ectasia.

Association between the chronic stimulation of endogenous nitric oxide that leads to vascular relaxation and the occurrence of areas of ectasia is another suggested mechanism [2]. According to Manginas, CAE occurs due to two different mechanisms in two distinct patient groups: (i) rarely in subjects without coronary atherosclerosis as a result of interstitial NO vascular overstimulation and (ii) commonly in patients with concomitant CAD due to severe and chronic arterial inflammation [10].

Genetic predisposition of coronary ectasia could be suggested from its association with angiotensin-converting enzyme DD genotype [17] and with hereditary conditions like familial hypercholesterolemia [18].

There is controversial association between hypertension and CAE [3,7,8]. According to Zeina et al. CAE is not correlated with diabetes mellitus, hypertension, hyperlipidemia, smoking and family history of CAD [7]. CAE is also related to apical hypertrophic cardiomyopathy with high wall tension especially during ventricular systole [19]. Left ventricular diastolic dysfunction was demonstrated in CAE by conventional and tissue Doppler imaging in a small study [20].

Formation of aneurysm may be seen following percutaneous coronary interventions [9]. These may occur during coronary balloon angioplasty, but more importantly following coronary stent placement, atherectomy and brachytherapy [10,21]. Injury of the media of a blood vessel has still the main responsibility after percutaneous revascularization procedure for coronary aneurysm development [9]. Cardiac involvement is the most important manifestation of Kawasaki disease and includes coronary artery aneurysms and ectasias, premature atherosclerosis, thrombosis, or occlusion with myocardial infarction [22]. Coronary aneurysms develop in 15–25% of untreated children with Kawasaki disease [22,23], but after the introduction of the aspirin and intravenous gamma globulin therapy, resolution occurs at least 50% of the cases [23]. Right coronary artery is the most frequently involved vessel in the coronary tree (40–61%) (Fig. 1) which is followed by the left anterior descending artery (15–32%) and left circumflex artery (15–23%) [1,3,6,7]. Isolated left main trunk ectasia is almost an exception. Ectasia is limited in one coronary artery in 75% of cases. CAE is mostly associated with obstructive coronary artery disease and isolated CAE has remarkably low incidence (<20%). CAE may coexist with aneurysms of other arterial beds, particularly abdominal aorta, even with venous varicosities. This finding is conversely not supported by Hartnell et al. [1].

4. Diagnosis

Gold standard in diagnosing coronary ectasia is coronary angiogram. IVUS is available for evaluation of luminal extension and vessel wall pathologies and also for identification of normal arterial segments adjacent to stenotic lesions, which are often falsely characterized as aneurysms by conventional

angiography [11]. Distortions in flow and washout are common in CAE, and are clearly associated with the severity of ectasia. Angiographic signs of turbulent and stagnant flow include delayed antegrade contrast filling, a segmental back flow (milking phenomenon) and local deposition of contrast in the dilated coronary segment (stasis) [5]. Other imaging methods like magnetic resonance angiography (MRA), multislice CT or the electron beam CT are also applicable for this vascular pathology [6]. However, CT should not be a choice as a technique for the follow up of patients because of its high radiation dose. Instead, MRA, being a non-invasive, non-radiating technique, may be utilized for follow up of CAE [5]. Transthoracic or transesophageal echocardiography may be option for the proximally located ectasias.

5. Clinical significance and symptoms

Clinical significance of CAE is not fully clarified. There is no typical symptom that could be associated with coronary ectasia. The symptoms may be associated with the concomitant CAD, Kawasaki disease or connective tissue disorder, although most of the patients are asymptomatic. Patients with CAE without significant coronary narrowing may still present with angina pectoris, positive stress tests, or acute coronary syndromes [24–26]. Decreased coronary flow velocity or stagnancy of coronary blood flow may cause exercise-induced angina regardless of coexisting stenotic coronary disease [5]. Additionally acute coronary syndromes may result from atherosclerotic lesions within ectatic regions of the coronary arteries which appear to be highly inflamed high-risk plaques with tendency to rupture. Formation of intracoronary thrombus and dissipation of microemboli to distal coronary tree may also be the subject of acute coronary syndrome, which is precipitated from sluggish flow in the ectatic coronary segments [7,27] (Fig. 2). Angiographic




Fig. 2 – Ectasia of LAD mid segment and intracoronary thrombi (arrow) in a 65 yo male patient presented with acute coronary syndrome.

findings such as topographical extent of CAE and corrected TIMI frame count are associated with severity of angina in patients with CAE [25]. Gulec et al. observed that in patients with isolated CAE, both epicardial flow and microvascular perfusion are diminished. Coronary microvascular perfusion is impaired even in the setting of normal epicardial flow [28]. CAE without significant epicardial stenosis may lead to exercise induced myocardial ischemia especially if coronary tree is diffusely involved [24]. Akyurek et al. measured the blood flow velocity and coronary flow reserve invasively by use of Doppler scanning flow wire in patients with isolated CAE and in a control group. They reported significantly higher volumetric coronary blood flow but reduced coronary flow reserve in patients with diffuse CAE, suggesting that microcirculatory dysfunction may be the underlying cause of exercise-induced myocardial ischemia in CAE [29]. Ectatic coronary arteries tend to develop vasospasms which may also bring angina or acute coronary syndrome [7,30].

Observation of isolated CAE among patients younger than age 50 must be suggestive of connective tissue disorders or vasculitides. In such circumstances further investigations must be under consideration. Moreover an overlooked diagnosis, Kawasaki disease must be realized in young adults presented with coronary aneurysm. The most important clinical features suggesting coronary aneurysms are due to Kawasaki disease are the history of Kawasaki disease compatible illness, Asian race, proximal location of coronary aneurysms, giant (>8 mm) aneurysms, young age (<30) and absence of significant coronary stenosis ($\geq 50\%$). Accurate diagnosis of Kawasaki disease is important because the management strategies differ from conventional atherosclerotic ectasias [31].

6. Prognosis

The prognosis of CAE depends directly on the severity of the concomitant coronary artery disease. CAE with obstructive coronary artery disease is a vicious condition because of its potential of resulting in several adverse cardiac events. Although no difference in mortality between patients with or without CAE was demonstrated, isolated ectasia still bears risk of myocardial ischemia and infarction [5,24,28,29]. According to the classification defined by Markis, type I and type II coronary ectasias bring about the worse prognosis than type III and IV. Mortality rate at 2 years is reported 15% [8]. No relation between diameter of ectasia and survival is reported.

7. Treatment

There is still no consensus for management of CAE. Conducting large scaled randomized trials which compares different treatment modalities is difficult because of relative rarity of this condition. In the case of accompanying CAD, the management is same as for CAD alone. Intense risk factor modification for primary and secondary prevention must be considered.

Administration of aspirin to all CAE patients is logical due to the high coincidence with coronary artery disease and

reported cases of myocardial infarction [5]. Statins may have a role by inhibiting matrix metalloproteinases [32]. Nitrates by dilating epicardial coronary arteries, may cause the steal syndrome and exacerbate anginal symptoms so are not recommended [9,26]. Isolated CAE has a better prognosis and the antiplatelet drugs underlie the therapy [5]. Management of isolated coronary artery ectasia in the cases with angina or myocardial ischemia includes acetylsalicylic acid, statin and antiischemic medications (calcium channel blocker, beta blocker and trimetazidine) as required [26,33,34] in addition to risk factor modification for atherosclerosis.

Acute coronary syndrome associated with CAE must be managed on an individual basis. Existence of thrombus may require to implement additional therapeutic decisions, i.e. thrombolysis, heparin infusion or glycoprotein IIb/IIIa receptor inhibitors as needed in the case of acute coronary syndrome [5,35-37] (Fig. 3). Thrombus aspiration during primary PCI should be considered [35]. Chronic anticoagulation is suggested by many authors however no randomized trial demonstrated its benefit on CAE. The anticipated benefit must be counterbalanced with the risk of hemorrhage. Percutaneous or surgical revascularization may be option among patients with coexisting obstructive lesions and significant ischemia despite medical therapy [5,38,39]. Coronary intervention of stenosis adjacent to ectasia has inherent difficulties with regards to optimal stent sizing, misplacement and embolization of the stent, early stent thrombosis and restenosis [5,40]. Extra care must be taken during stenting because adequate stent expansion and wall apposition is needed [10]. The implantation of covered stents offers superior results compared to the bare metal stents, but long term benefit has not been adequately proven [40]. Coronary aneurysm formation after drug eluting stent implantation is also notified as a rare complication [41,42]. Parallel stenting with



Fig. 3 – A 56 yo male patient presented with acute anterior MI. Diffuse ectasia and acute thrombotic occlusion was seen in LAD and huge diagonal artery.

two drug eluting stent has been reported in an ectatic coronary artery stenting [43]. The use of large sized peripheral stents in ectatic coronary arteries also may be possible [44]. Indications for surgical treatment are identical to those in the case of coronary heart disease [9]. Additionally in those patients with evidence of enlargement of saccular coronary artery aneurysms with increased risk of rupture surgical resection may be an alternative [45,46]. As previously mentioned the usage of aspirin and intravenous gamma globulin therapy reduces the occurrence of coronary ectasias in patients with Kawasaki disease [23].

8. Conclusion

CAE is a vascular disease mostly a form of atherosclerosis seen in 0.3–4.9% of diagnostic coronary angiography procedures. A pattern of vascular remodeling, exaggerated expansive remodeling with enzymatic degradation of the extracellular matrix and thinning of the vessel media as a result of chronic inflammation is thought to be a major pathophysiologic process. The symptoms may be associated with the concomitant CAD, Kawasaki disease or connective tissue disorder although most of the patients are asymptomatic. Clinical importance especially leans on its association with acute coronary events. Treatment options include, risk factor modifications for CAD, antiischemic therapy, antithrombotic management and percutaneous or surgical revascularization techniques. Future trials are warranted in order to optimize the management of CAE.

REFERENCES

- [1] G.G. Hartnell, B.M. Parnell, R.B. Pridie, Coronary artery ectasia. Its prevalence and clinical significance in 4993 patients, *British Heart Journal* 54 (4) (1985) 392–395.
- [2] V.L. Sorrell, M.J. Davis, A.A. Bove, Current knowledge and significance of coronary artery ectasia: a chronologic review of the literature, recommendations for treatment, possible etiologies, and future considerations, *Clinical Cardiology* 21 (3) (1998) 157–160.
- [3] P.S. Swaye, L.D. Fisher, P. Litwin, et al., Aneurysmal coronary artery disease, *Circulation* 67 (1) (1983) 134–138.
- [4] M. Syed, M. Lesch, Coronary artery aneurysm: a review, *Progress in Cardiovascular Diseases* 40 (1) (1997) 77–84.
- [5] S. Mavrogeni, Coronary artery ectasia: from diagnosis to treatment, *Hellenic Journal of Cardiology: HJC=Hellenike kardiologike epitheorese* 51 (2) (2010) 158–163.
- [6] M. Diaz-Zamudio, U. Bacilio-Perez, M.C. Herrera-Zarza, et al., Coronary artery aneurysms and ectasia: role of coronary CT angiography, *Radiographics* 29 (7) (2009) 1939–1954.
- [7] A.R. Zeina, D. Sharif, J. Blinder, et al., Noninvasive assessment of coronary artery ectasia using multidetector computed tomography, *Coronary Artery Disease* 18 (3) (2007) 175–180.
- [8] J.E. Markis, C.D. Joffe, P.F. Cohn, et al., Clinical significance of coronary arterial ectasia, *The American Journal of Cardiology* 37 (2) (1976) 217–222.
- [9] A.I. Gziut, R.J. Gil, Coronary aneurysms, *Polskie Archiwum Medycyny Wewnietrznej* 118 (12) (2008) 741–746.
- [10] A. Manginas, D.V. Cokkinos, Coronary artery ectasias: imaging, functional assessment and clinical implications, *European Heart Journal* 27 (9) (2006) 1026–1031.
- [11] A.P. Antoniadis, Y.S. Chatzizisis, G.D. Giannoglou, Pathogenetic mechanisms of coronary ectasia, *International Journal of Cardiology* 130 (3) (2008) 335–343.
- [12] P. Schoenhagen, K.M. Ziada, D.G. Vince, et al., Arterial remodeling and coronary artery disease: the concept of dilated versus obstructive coronary atherosclerosis, *Journal of the American College of Cardiology* 38 (2) (2001) 297–306.
- [13] Y.S. Chatzizisis, A.U. Coskun, M. Jonas, et al., Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior, *Journal of the American College of Cardiology* 49 (25) (2007) 2379–2393.
- [14] D.P. Mason, R.D. Kenagy, D. Hasenstab, et al., Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery, *Circulation Research* 85 (12) (1999) 1179–1185.
- [15] H. Turhan, A.R. Erbay, A.S. Yasar, et al., Comparison of C-reactive protein levels in patients with coronary artery ectasia versus patients with obstructive coronary artery disease, *The American Journal of Cardiology* 94 (10) (2004) 1303–1306.
- [16] M. Savino, Q. Parisi, G.G. Biondi-Zoccai, et al., New insights into molecular mechanisms of diffuse coronary ectasias: a possible role for VEGF, *International Journal of Cardiology* 106 (3) (2006) 307–312.
- [17] S. Gulec, O. Aras, Y. Atmaca, et al., Deletion polymorphism of the angiotensin I converting enzyme gene is a potent risk factor for coronary artery ectasia, *Heart* 89 (2) (2003) 213–214.
- [18] K. Sudhir, T.A. Ports, T.M. Amidon, et al., Increased prevalence of coronary ectasia in heterozygous familial hypercholesterolemia, *Circulation* 91 (5) (1995) 1375–1380.
- [19] M. Saotome, H. Satoh, A. Uehara, et al., Coronary ectasia with slow flow related to apical hypertrophic cardiomyopathy—a case report, *Angiology* 56 (1) (2005) 103–106.
- [20] M. Saglam, I. Barutcu, O. Karakaya, et al., Assessment of left ventricular functions in patients with isolated coronary artery ectasia by conventional and tissue Doppler imaging, *Angiology* 59 (3) (2008) 306–311.
- [21] J.A. Condado, R. Waksman, O. Gurdziel, et al., Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans, *Circulation* 96 (3) (1997) 727–732.
- [22] H. Kato, T. Sugimura, T. Akagi, et al., Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients, *Circulation* 94 (6) (1996) 1379–1385.
- [23] J.W. Newburger, J.C. Burns, Kawasaki disease, *Vascular Medicine* 4 (3) (1999) 187–202.
- [24] T. Sayin, O. Doven, B. Berkalp, et al., Exercise-induced myocardial ischemia in patients with coronary artery ectasia without obstructive coronary artery disease, *International Journal of Cardiology* 78 (2) (2001) 143–149.
- [25] T.A. Zografos, S. Korovesis, E. Giazitzoglou, et al., Clinical and angiographic characteristics of patients with coronary artery ectasia, *International Journal of Cardiology* (2012).
- [26] D. Kruger, U. Stierle, G. Herrmann, et al., Exercise-induced myocardial ischemia in isolated coronary artery ectasias and aneurysms (dilated coronopathy), *Journal of the American College of Cardiology* 34 (5) (1999) 1461–1470.
- [27] S.T. Rab, D.W. Smith, B.N. Alimurung, et al., Thrombolytic therapy in coronary ectasia and acute myocardial infarction, *American Heart Journal* 119 (4) (1990) 955–957.
- [28] S. Gulec, Y. Atmaca, M. Kilickap, et al., Angiographic assessment of myocardial perfusion in patients with isolated coronary artery ectasia, *The American Journal of Cardiology* 91 (8) (2003) 996–999 A997.

- [29] O. Akyurek, B. Berkalp, T. Sayin, et al., Altered coronary flow properties in diffuse coronary artery ectasia, *American Heart Journal* 145 (1) (2003) 66–72.
- [30] H. Suzuki, Y. Takeyama, Y. Hamazaki, et al., Coronary spasm in patients with coronary ectasia, *Catheterization and Cardiovascular Diagnosis* 32 (1) (1994) 1–7.
- [31] L.B. Daniels, M.S. Tjajadi, H.H. Walford, et al., Prevalence of Kawasaki disease in young adults with suspected myocardial ischemia, *Circulation* 125 (20) (2012) 2447–2453.
- [32] M. Massaro, A. Zampolli, E. Scoditti, et al., Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability, *Cardiovascular Research* 86 (2) (2010) 311–320.
- [33] H. Turhan, E. Yetkin, What is the plausible strategy for the management of patients with isolated coronary artery ectasia and myocardial ischemia?, *International Journal of Cardiology* 117 (2) (2007) 285–286.
- [34] A. Dogan, M. Ozaydin, O. Gedikli, et al., Effect of trimetazidine on exercise performance in patients with coronary artery ectasia, *Japanese Heart Journal* 44 (4) (2003) 463–470.
- [35] P.G. Steg, S.K. James, D. Atar, et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, *European Heart Journal* 33 (20) (2012) 2569–2619.
- [36] G.N. Levine, E.R. Bates, J.C. Blankenship, et al., 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions, *Circulation* 124 (23) (2011) e574–e651.
- [37] Y. Tanabe, E. Itoh, I. Nakagawa, K. Suzuki, Pulse-spray thrombolysis in acute myocardial infarction caused by thrombotic occlusion of an ectatic coronary artery, *Circulation Journal: Official Journal of the Japanese Circulation Society* 66 (2) (2002) 207–210.
- [38] I.P. Antonellis, S.P. Patsilinos, C.A. Pamboukas, et al., Sealing of coronary artery aneurysm by using a new stent graft, *Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions* 48 (1) (1999) 96–99.
- [39] M. Ochiai, T. Yamaguchi, J. Taguchi, et al., Angioplasty of stenoses adjacent to aneurysmal coronary artery disease, *Japanese Heart Journal* 31 (6) (1990) 749–757.
- [40] C. Stefanadis, K. Toutouzas, E. Tsiamis, P. Toutouzas, New stent design for autologous venous graft-covered stent preparation: first human application for sealing of a coronary aneurysm, *Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions* 55 (2) (2002) 222–227.
- [41] R. Zbinden, P. Eshthardi, S. Cook, Coronary aneurysm formation in a patient early after everolimus-eluting stent implantation, *The Journal of Invasive Cardiology* 20 (5) (2008) E174–E175.
- [42] J.P. Levisay, R.M. Roth, R.A. Schatz, Coronary artery aneurysm formation after drug-eluting stent implantation, *Cardiovascular Revascularization Medicine: Including Molecular Interventions* 9 (4) (2008) 284–287.
- [43] S.W. Rha, S.P. Wani, D.J. Oh, Parallel stenting using two sirolimus-eluting stents in an ectatic coronary artery stenosis, *Heart* 93 (8) (2007) 976.
- [44] M. Agirbasli, D.C. Morris, J.J. Marshall, The use of intrastent peripheral stent in large coronary arteries: report of three cases, *Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography and Interventions* 50 (4) (2000) 498–501.
- [45] E. Yetkin, J. Waltenberger, Novel insights into an old controversy: is coronary artery ectasia a variant of coronary atherosclerosis?, *Clinical Research in Cardiology: Official Journal of the German Cardiac Society* 96 (6) (2007) 331–339.
- [46] R. Vijayanagar, E. Shafii, M. DeSantis, et al., Surgical treatment of coronary aneurysms with and without rupture, *The Journal of Thoracic and Cardiovascular Surgery* 107 (6) (1994) 1532–1535.